Shockwave therapy has a meaningful clinical evidence base for chronic low back pain. Meta-analyses of randomized trials report reductions in pain and, in many analyses, disability. A 2026 network meta-analysis found the most favorable results when shockwave (extracorporeal shockwave therapy, ESWT) was combined with conventional physical therapy. The evidence also has clear limits. Results vary by study and by what shockwave is compared against, at least one well-designed trial found no added benefit on disability, and no single device, dose or protocol has been established. Most trials studied chronic nonspecific low back pain, which is not the same thing as disc herniation, sciatica, stenosis, fracture, infection, or every other cause of back pain. Shockwave is not a replacement for exercise or for a diagnosis. This review covers what the strongest studies found and where they stop.
What is shockwave therapy?
Shockwave therapy delivers short, high-pressure acoustic pulses into tissue from a handpiece on the skin. Radial shockwave spreads its energy across a broad, relatively superficial area. Focused shockwave concentrates energy at a chosen depth. Both have been studied in chronic low back pain, using many different settings. For a general introduction, see our shockwave therapy overview.
Which low back pain does this research apply to?
Mostly chronic nonspecific low back pain: pain lasting three months or longer that is not attributed to a specific structural cause such as a fracture, infection, tumor, or a clear nerve-root problem. That distinction matters. The trial results below should not be assumed to apply to:
- Sciatica or radiculopathy, where pain travels down the leg with nerve signs
- Clinically significant spinal stenosis
- Progressive weakness or other worsening neurologic deficit
- Fracture, infection, cancer, or inflammatory spinal disease
- Cauda equina syndrome, which is a medical emergency
- Acute traumatic back pain or complications after spine surgery (one post-surgical trial is discussed separately below)
Leg-dominant nerve symptoms need a different assessment, covered on our sciatica and nerve entrapment page.
Does shockwave therapy help chronic low back pain?
On average, the pooled evidence says it can reduce pain and disability, at least over weeks to a few months.
A 2023 meta-analysis of 12 randomized trials. Liu and colleagues, in the Journal of Orthopaedic Surgery and Research, pooled 12 randomized trials with 632 patients. Compared with the control treatments, shockwave produced more pain relief at 4 weeks (about 1.0 point lower on a 0–10 scale) and 12 weeks (about 0.9 points lower). Disability on the Oswestry Disability Index (ODI, a 0–100 scale) was about 4 points lower at 4 weeks and 4.5 points lower at 12 weeks. There was no significant effect on mental health scores, and no serious adverse effects were reported. The control groups did not all receive the same thing: shockwave was compared against a range of other treatments, so this result does not mean shockwave beats any one specific therapy.
A broader 2023 meta-analysis of 22 studies. Wu and colleagues, in Medicine, pooled 22 studies with 1,749 patients. Pain was about 1.1 points lower and ODI about 6 points lower with shockwave than with other therapies after treatment, and the differences remained at three months (pain about 1.3 points lower, ODI about 6 points lower). The authors reported possible publication bias for the ODI result, though a correction did not change its direction, and they called for larger trials with more objective outcomes. This review included low back pain broadly and searched Chinese as well as English-language databases, so its trials are more varied.
These are average differences across many patients. They do not predict how any one person will respond.
What the 2026 network meta-analysis found
The most recent pooled analysis asks a more practical question: is shockwave better alone, or as part of rehabilitation?
Qiao and colleagues, in Frontiers in Physiology, searched through April 2026 and compared four options across randomized trials: shockwave combined with conventional physical therapy, shockwave alone, conventional physical therapy alone, and sham shockwave. Fourteen trials reported pain and eight reported function.
- Combined therapy ranked first for both pain relief and function. Ranking scores (SUCRA) were 96.0% for pain and 99.3% for function.
- Combined therapy vs. physical therapy alone: greater pain relief (standardized mean difference −0.88) and a larger ODI improvement (about 5 points).
- Shockwave alone vs. sham: shockwave reduced pain (standardized mean difference −1.22).
- Function: combined therapy improved ODI more than shockwave alone, physical therapy alone, or sham. The authors noted that shockwave on its own did not show a significant effect on function.
SUCRA scores are probability rankings within a network of trials. They do not prove that one treatment is best for everyone. The authors concluded that combined therapy "shows promise" and that more high-quality randomized trials are needed. The practical reading is that this supports using shockwave as an adjunct to rehabilitation rather than automatically treating it as a replacement.
Not every trial shows an added benefit
Pooled averages can hide trials that point the other way.
Taheri and colleagues (2021). In a randomized trial in Archives of Physical Medicine and Rehabilitation, 32 adults with chronic low back pain received oral medication and an exercise program, plus either real or sham shockwave once a week for four weeks. Pain improved substantially in both groups. At three months the average pain score was 1.8 in the shockwave group and 1.1 in the sham group, and disability scores did not differ between groups. The trial was small and excluded people with disc degeneration, prior back surgery, fracture, infection, or cancer. When everyone already receives medication and exercise, shockwave did not add a clear benefit on disability in this trial.
Rajfur and colleagues (2022). In 40 patients with chronic low back pain and L5–S1 disc changes, all of whom did the same stabilization training, focused shockwave reduced pain more than sham immediately after the treatment course. At one and three months the difference between groups was no longer significant, and disability improved similarly in both groups. This is one of the few focused shockwave trials in the low back. It does not show that focused shockwave repairs or regenerates a disc.
These results do not cancel out the meta-analyses. They show that the size of any added benefit depends on what else the patient is receiving, how long they are followed, and which outcome is measured.
Does the shockwave protocol matter?
Probably, but the best protocol is not settled.
Intensity and number of sessions. Sun and colleagues, in Pain Physician (2022), randomized 69 patients to the same total energy dose delivered two ways: six sessions at low intensity or two sessions at medium intensity over two weeks. The low-intensity, more-session group had lower pain with movement at 2, 4 and 6 weeks, and lower disability at 2 and 6 weeks. By three months there was no difference between groups. More energy per session was not automatically better.
The applicator. Back and colleagues, in Clinical Rehabilitation (2024), ran a triple-blind trial in 81 people with chronic nonspecific low back pain. A single session of radial shockwave (2,000 pulses, 100 mJ, 5 Hz) with a concave applicator tip lowered pain by about two points compared with placebo immediately afterward, and raised the pressure needed to provoke pain. A convex tip did less. This measured the effect of one session, right after it ended. It says nothing about lasting benefit, but it does suggest that equipment details can change the result.
No single trial should set a clinic's protocol. Together, these studies show that dose, session number and applicator are still being worked out.
Does shockwave affect fibrosis or scar tissue?
The trials above measure pain and function. Two other studies look at scar-like tissue more directly. Neither is about ordinary nonspecific low back pain, so neither should be read as evidence for it.
Scar tissue after spine surgery (2025). Rashad and colleagues, in the Annals of Rehabilitation Medicine, studied 60 patients with low back pain and sciatica caused by epidural fibrosis, scar tissue that can form around the nerve roots after a laminectomy. Both groups received conventional physical therapy, and one group also received radial shockwave. Pain fell in both groups, and more in the shockwave group. Lumbar range of motion improved, and nerve-conduction measures (F-wave latency and chronodispersion) shortened, only in the shockwave group. This is surgical scar around a nerve, a different problem from everyday back pain, and the results should not be applied to people who have not had spine surgery.
Immobilized muscle in rabbits (2021). Huang and colleagues, in the American Journal of Physical Medicine & Rehabilitation, casted rabbits' knees for four weeks to produce muscle fibrosis and joint contracture, then compared natural recovery, radial shockwave, ultrashort-wave diathermy, and the two combined. The combination gave the best recovery of knee motion and was more effective than either treatment alone against muscle fibrosis, collagen deposition, and overexpression of TGF-β1 and HIF-1α, two signals that drive fibrosis. This is a mechanism study in immobilized animal muscle. It suggests how shockwave might act on fibrotic muscle. It is not evidence that shockwave clears adhesions in a human lower back.
Is radial or focused shockwave better for low back pain?
The research has not shown one to be better. Both radial and focused shockwave have been studied in chronic low back pain, using different settings and comparison groups, and head-to-head trials in the low back are lacking. The choice depends on the target the exam identifies: broad, superficial muscle and fascia for radial; a smaller or deeper target for focused. Our radial vs. focused shockwave article explains the physics.
Can shockwave heal a lumbar disc?
No human evidence shows that it does. The clinical trials in this review measure pain and function. They do not show disc regeneration, reversal of degeneration, decompression of a nerve root, or treatment of spinal stenosis itself. A degenerated disc on an MRI is also not automatically the source of pain, as we explain in spinal degeneration and low back pain.
Why the thoracolumbar fascia comes up
Shockwave in the low back is usually aimed at the paraspinal muscles and the thoracolumbar fascia, the broad connective-tissue sheet over them. The fascia is built in layers that normally glide past one another as the trunk bends.
Langevin and colleagues (2011). In the best-known study of that gliding, published in BMC Musculoskeletal Disorders, researchers used ultrasound to measure shear strain, how much the fascial layers slide, during passive forward bending. In 71 people with low back pain lasting more than 12 months, shear strain was about 20% lower than in 50 people without back pain (56.4% vs. 70.2%). In men, lower shear strain went with thicker and more echogenic connective tissue around the muscles, less trunk motion, and slower performance on repeated bending and sit-to-stand tasks. The authors suggested the reduced sliding may reflect abnormal movement patterns, changes in the connective tissue itself, or both. This is the human finding most often cited when clinicians talk about fascial restriction or adhesion.
It is one study, measured at one point in time, and it did not test any treatment. Later work has been mixed: a 2026 meta-analysis found the fascia thicker and stiffer on average in people with low back pain, but sliding results pointed in opposite directions across studies. None of this shows that shockwave changes fascial sliding, or that fascia is the cause in every patient. We cover that research in thoracolumbar fascia and low back pain.
Evidence at a glance
| Study | Design and size | Comparison | Main finding | Key limitation |
|---|---|---|---|---|
| Liu et al., 2023 | Meta-analysis, 12 RCTs, 632 patients | Shockwave vs. mixed other treatments | Less pain and disability at 4 and 12 weeks | Comparators varied |
| Wu et al., 2023 | Meta-analysis, 22 studies, 1,749 patients | Shockwave vs. other therapies | Less pain and disability, still present at 3 months | Mixed designs; possible publication bias for ODI |
| Qiao et al., 2026 | Network meta-analysis, 14 pain and 8 function RCTs | Shockwave + PT vs. shockwave, PT, sham | Combination ranked highest for pain and function | Rankings do not prove universal superiority |
| Taheri et al., 2021 | RCT, 32 patients | Shockwave vs. sham, both with medication and exercise | Both groups improved; no difference in disability | Small sample |
| Rajfur et al., 2022 | RCT, 40 patients | Focused shockwave vs. sham, both with stabilization training | More pain relief right after treatment; no difference at 1 and 3 months | Small sample; short follow-up |
| Back et al., 2024 | Triple-blind RCT, 81 patients | Single radial session, two tips vs. placebo | Concave tip lowered pain about 2 points immediately | Immediate effect only |
How we use this research
The evidence supports shockwave as one option for selected people with chronic low back pain, especially as part of active rehabilitation. It does not support it as a cure, as a substitute for exercise, or as treatment for every back condition. Exercise, staying active, and medical, physical therapy, injection or surgical care when indicated all remain part of good back care.
We start with an exam to determine what appears clinically relevant: muscle and fascia, spinal and hip findings, load tolerance, and any nerve or red-flag signs. If shockwave fits, we explain why and what results are realistic. If it does not, we say so. See how we approach chronic low back pain treatment, compare our tools on the services page, or book a new patient exam.
Sources
- Liu K, Zhang Q, Chen L, et al. Efficacy and safety of extracorporeal shockwave therapy in chronic low back pain: a systematic review and meta-analysis of 632 patients. Journal of Orthopaedic Surgery and Research. 2023;18(1):455. PMID 37355623. (link)
- Wu Z, Zhou T, Ai S. Extracorporeal shock wave therapy for low back pain: a systematic review and meta-analysis. Medicine (Baltimore). 2023;102(52):e36596. PMID 38206739. (link)
- Qiao Z, Xi S, Yang K, et al. Efficacy of extracorporeal shock wave therapy combined with conventional physical therapy for chronic low back pain: a systematic review and network meta-analysis of randomized controlled trials. Frontiers in Physiology. 2026;17:1807929. PMID 42359248. (link)
- Taheri P, Khosrawi S, Ramezani M. Extracorporeal shock wave therapy combined with oral medication and exercise for chronic low back pain: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation. 2021;102(7):1294-1299. PMID 33453192. (link)
- Rajfur K, Rajfur J, Matusz T, et al. Efficacy of focused extracorporeal shock wave therapy in chronic low back pain: a prospective randomized 3-month follow-up study. Medical Science Monitor. 2022;28:e936614. PMID 35689370. (link)
- Sun H, Chen H, Mu G, et al. Comparison of different treatment regimens of extracorporeal shockwave therapy in chronic low-back pain: a randomized controlled trial. Pain Physician. 2022;25(8):E1211-E1218. PMID 36375191. (link)
- Rashad UM, Abousenna MH, Elsamman AK, Rehab NI. Effect of extracorporeal shock wave therapy on post-laminectomy lumbar epidural fibrosis. Annals of Rehabilitation Medicine. 2025;49(2):81-90. PMID 40312273. (link)
- Huang PP, Zhang QB, Zhou Y, et al. Effect of radial extracorporeal shock wave combined with ultrashort wave diathermy on fibrosis and contracture of muscle. American Journal of Physical Medicine & Rehabilitation. 2021;100(7):643-650. PMID 32969968. (link)
- Langevin HM, Fox JR, Koptiuch C, et al. Reduced thoracolumbar fascia shear strain in human chronic low back pain. BMC Musculoskeletal Disorders. 2011;12:203. PMID 21929806. (link)
- Back CGN, Peron R, Lopes CVR, et al. Immediate effect of extracorporeal shockwave therapy in patients with chronic non-specific low back pain: a randomised placebo-controlled triple-blind trial. Clinical Rehabilitation. 2024;38(8):1080-1090. PMID 38710199. (link)
